Call 1300 658 508
What is the Targeted Translation Research Accelerator Grant Opportunity?
The 2020 Targeted Translation Research Accelerator Grant Opportunity is a scheme to deliver the Accelerator as a comprehensive package of activities to improve outcomes for diabetes and cardiovascular disease.
The 2020 Targeted Translation Research Accelerator Grant Opportunity was announced as part of the Medical Research Future Fund and is an Initiative under the Preventive and Public Health Research Initiative.
The objective of the Targeted Translation Research Accelerator Grant opportunity is to support the development of novel preventive, diagnostic and therapeutic approaches and products for diabetes and cardiovascular disease.
The successful independent organisation will be responsible for ensuring that the Accelerator:
- establishes through competitive processes two research centres, one for diabetes and one for cardiovascular disease to accelerate therapies for the prevention, early detection and treatment of disease related complications
- supports through competitive processes research projects on the potential common pathways interactions, and complexities for patients experiencing two or more of the following: Type 1 diabetes; Type 2 diabetes; and cardiovascular disease
- targets investment and related support through partnership projects to progress promising drug and device development projects, with a focus on promoting commercialisation of novel therapeutics and devices for diabetes and cardiovascular disease
- sources, nurtures and invests in early stage therapeutic research targets to transform diagnostic and therapeutic care for people with diabetes
- commissions and conducts research to support the health and commercial sectors to deliver transformations in diabetes and cardiovascular disease.
The expected outcome of the research funded through partnership projects with the independent organisation selected under the grant opportunity is to improve knowledge and its translation into practice in order to reduce the burden of diabetes and cardiovascular disease.
The Australian Government agreed a total of $125 million over nine years, in the 2018-19 Budget to progress early stage diabetes and cardiovascular disease research.
For this grant opportunity, up to $47 million is available over four years from 2019-20 to 2022-23. There is the potential for this grant to be extended up to a maximum of 10 years.
Call 1300 658 508
To be eligible for the Targeted Translation Research Accelerator Grant opportunity, your project must:
- be aimed at the objectives
- have no more than $47 million in eligible expenditure
- include one or more of the following eligible activities:
- employment of personnel and/or
- other direct research costs.
To be eligible for the Targeted Translation Research Accelerator Grant opportunity, you must:
- have an Australian Business Number (ABN)
- be incorporated in Australia
and in accordance with s20 and s24 of the Medical Research Future Fund Act 2015, be one of the following entities:
- a medical research institute
- a university
- a corporate Commonwealth entity
- a corporation (including businesses and not for profits)
- a state or territory government entity.
Joint applications are encouraged, provided you have a lead organisation who is the main driver of the project and is eligible to apply.
Call 1300 658 508
Nine of the projects will receive a total of $6.7 million from the Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator (TTRA) program. All of these projects target aspects of diabetes and cardiovascular disease, which are leading causes of death and disability.
The projects include development of an artificial heart and the use of genetically engineered islet cells to restore glucose control in people with type 1 diabetes.
The new Research Centres are:
- The Australian Centre for Accelerating Diabetes Innovations (ACADI)
- The Australian Stroke & Heart Research Accelerator (ASHRA)
Each Centre has been awarded $10 million over four years through the Australian Government’s Medical Research Future Fund, with the University of Sydney’s Professor Clara Chow announced as ASHRA director for the first year.
Round 2 Recipients
BiVACOR Pty Ltd received $750,000 to develop a new, more portable external controller to allow long-term use with its BiVACOR total artificial heart.
BiVACOR® is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology.
Cardihab Pty Ltd received $740,153 to advance its platform and patient-centric smart phone-based app, providing personalised healthcare delivery to improve heart failure outcomes.
Cardihab® is a digital health company that exists to help patients reach optimal health when at risk of, or living with, heart disease.
Cyban Pty Ltd received $700,000 to apply its innovative brain pulse oximeter technology, as a point of care monitor for earlier detection and treatment of stroke in a hospital setting to prevent long term disability and death.
Cyban enables confident clinical care at every stage of the patient journey through patented technology that delivers accurate results quickly.
Deakin University received $749,764 award to trial an online education program for prevention, awareness of symptoms, and treatment to reduce hypoglycaemia-related anxiety and improve mental health outcomes in adults with type 1 diabetes.
Deakin University aims to be a catalyst for positive change for the individuals and the communities it serves. This will be achieved by ensuring their teaching, research, partnerships and international programs are relevant, innovative and responsive.
Garvan Institute of Medical Research received $749,979 to conduct a first-in-human safety and efficacy trial using genetically engineered islet cells to restore glucose in type 1 diabetes.
The Garvan Institute of Medical Research was founded in 1963 and is one of the world’s leading centres of excellence in basic and translational science. Its researchers have made significant advances in genome, epigenome, protein and cell analysis technology.
Monash University received $750,000 to develop a novel adjunctive peptide therapy to lower insulin doses for improved glucose control in the treatment of type 1 diabetes.
Monash University is Australia’s largest and most international university. Its extensive educational offering, delivered via our 10 faculties, includes undergraduate, postgraduate and research courses. Monash is a research-intensive university, known for some significant and lasting discoveries that have delivered impact beyond the academic community.
University of Sydney received $750,000 to bring oral insulin to phase I clinical studies using a novel quantum dot drug delivery platform
The University of Sydney was the first university to be established in Australasia and is one of Australia’s top universities. They aim to maximise the potential of the brightest researchers and most promising students, whatever their social or cultural background – regardless of race, religion or social class.
University of Sydney received $749,536 to progress novel small molecule therapeutics targeting the inflammatory contribution to atherosclerosis, stabilising plaque and preventing heart attack.
Western Sydney University received $744,873 to trial a clinically validated Care Portal providing access to peer support, mental health support and clinical care, empowering young Australians to live well with diabetes
Western Sydney University offers unlimited potential to students with the talent, drive and ambition to succeed.